Threshold Pharmaceuticals Inc. (NASDAQ:THLD) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 611,915 shares, a drop of 56.1% from the October 31st total of 1,393,470 shares. Based on an average trading volume of 836,458 shares, the short-interest ratio is presently 0.7 days. Approximately 0.9% of the shares of the stock are short sold.
A number of hedge funds have recently modified their holdings of THLD. First Eagle Investment Management LLC boosted its stake in shares of Threshold Pharmaceuticals by 86.7% in the third quarter. First Eagle Investment Management LLC now owns 5,974,802 shares of the biotechnology company’s stock worth $4,048,000 after buying an additional 2,775,369 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 500,000 shares during the period. Deerfield Management Co. acquired a new position in Threshold Pharmaceuticals during the second quarter worth $1,641,000. BlackRock Institutional Trust Company N.A. raised its position in Threshold Pharmaceuticals by 18.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,489,439 shares of the biotechnology company’s stock worth $1,009,000 after buying an additional 233,528 shares during the period. Finally, KCG Holdings Inc. acquired a new position in Threshold Pharmaceuticals during the third quarter worth $238,000. Institutional investors and hedge funds own 27.04% of the company’s stock.
Threshold Pharmaceuticals (NASDAQ:THLD) opened at 0.506 on Tuesday. The company has a market capitalization of $36.21 million, a price-to-earnings ratio of 0.841 and a beta of 4.78. Threshold Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $3.90. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.63.
Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Equities research analysts anticipate that Threshold Pharmaceuticals will post ($0.36) earnings per share for the current fiscal year.
Several research firms have weighed in on THLD. S&P Equity Research lowered their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a report on Friday, September 30th. William Blair reiterated an “outperform” rating on shares of Threshold Pharmaceuticals in a research report on Monday, October 3rd.
Threshold Pharmaceuticals Company Profile